Trial Profile
Phase I Study of Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Oct 2022
Price :
$35
*
At a glance
- Drugs Defactinib (Primary) ; Gemcitabine (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- 13 Oct 2022 Results published in the Clinical Cancer Research
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 18 Jul 2021 Status changed from active, no longer recruiting to completed.